Barr nets deal to supply adenovirus vaccines to U.S. military

The U.S. Army Medical Materiel Development Activity (USAMMDA) recently awarded a Full Rate Production Contract to Barr Laboratories to supply adenovirus vaccines through the Defense Logistics Agency (DLA).

The contract stipulates that the lab's vaccines for adenovirus serotypes four and seven would be administered in all basic-training facilities for the U.S. armed forces through 2019. The company's vaccines have been in use by the military since 2011, and the Naval Health Research Center has reported that the vaccines have a 99 percent effectiveness rating, preventing approximately 50,000 cases of Febrile Respiratory Illness. The center equates this to 150,000 training days saved that would have been lost to the illness through sick soldiers.

Adenovirus Vaccine Product Manager for the Pharmaceutical Systems Project Management Office of the USAMMDA Dr. Clifford Snyder said that between 1999 and 2010, there were at least four fatalities attributed to adenovirus illnesses. During that period, the vaccines were not available.

"Resumption of adenovirus vaccine use has undoubtedly saved lives, as well as helped keep recruits healthy in training," Snyder said. "(The awarding) of the DLA contract will ensure that this critical vaccine is available for all services for the foreseeable future."